- Poster presentation
- Open Access
Modulation of the immune response in HTLV-1-infections by SM29 antigen in vitro is dependent of IL-10, TGF-β and CTLA-4
Retrovirology volume 11, Article number: P68 (2014)
The HTLV-1 is the causal agent of HTLV-1-associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP). The immune response in HTLV-1 infection is polarized to the Th1-type, and previous data from our group had demonstrated that the use of Schistosoma antigens to cell cultures in HTLV-1 infection resulted in down-modulation of Th1/inflammatory response. The aim of this study was to evaluate whether the modulation of inflammatory response by S. mansoni antigens depends upon the presence of IL-10, TGF-β and CTLA-4. The antibodies anti-IL-10, anti-TGF-β and anti-CTLA-4 with or without the S. mansoni antigen Sm29 were added to the PBMC cultures of HTLV-1- infected individuals and the levels of cytokines in the supernatants were measure using ELISA sandwich method. Compared to the levels of cytokine in non stimulated cultures (1.073 pg/ml, median values), the levels of IFN-gproduction (552 pg/ml, 1.002 pg/ml and 548 pg/ml, respectively; p<0.05). On the other hand, the levels of IL-10 were increased by the presence of Sm29 (it passed from 26 pg/ml to102 pg/ml; p=0.02), however when anti-TGF-β and anti-CTLA-4 were added to the cultures there was a reduction in the levels of IL-10 (19 pg/ml and 23 pg/ml, respectively; p<0.05). The regulation of IFN-y production by Sm29 antigen in HTLV-1-infected individuals is dependent on IL-10, TGF-β and CTLA-4. Also the levels of IL-10 were affected by the neutralization of TGF-β and CTLA-4.
CNPQ (Universal 479417/2008 3), NIH (R01AI079238A).
About this article
Cite this article
Lima, L.M., Santos, S.B., Oliveira, R.R. et al. Modulation of the immune response in HTLV-1-infections by SM29 antigen in vitro is dependent of IL-10, TGF-β and CTLA-4. Retrovirology 11, P68 (2014). https://doi.org/10.1186/1742-4690-11-S1-P68
- Immune Response
- Cell Culture
- Infectious Disease
- Inflammatory Response
- Cancer Research